Scholarlink

Background <p>Hormone receptor-positive, HER2-negative (HR + /HER2-) breast cancer generally has a favorable prognosis; however, early postoperative recurrence markedly reduces survival. Accurate prediction of early recurrence is crucial for personalizing treatment. This case–control study compared MammaPrint (MP) and BluePrint (BP) results between early recurrence patients and matched controls.</p> Methods <p>Patients were selected from our previous study, the WJOG15721B cohort (n = 2732). Those with recurrence within three years after surgery were randomly extracted, and controls matched for institution, clinical stage, and number of pathological lymph node metastases were included (n = 124). Tumor samples underwent MP and BP assays to classify recurrence risk and molecular subtypes.</p> Results <p>Of 115 submitted tumor samples, 85 were analyzed successfully (43 early recurrence, 42 no recurrence). High-risk MP classification was significantly more frequent in early recurrence patients (79.1% vs. 40.5%, p &lt; 0.001), and Luminal B BP subtype was more common in early recurrence patients (79.1% vs. 38.1%, p &lt; 0.001). High MP risk was associated with high Ki-67 levels and higher nuclear grade. Integrating clinical and genomic risk enhanced prognostic precision: patients with both clinical and genomic high risk had the highest recurrence rate (100%), those with low clinical and genomic risk had the lowest (28.1%), and patients with low clinical but high genomic risk showed an intermediate recurrence rate (57.5%).</p> Conclusions <p>Compared with patients without recurrence, those with early recurrence showed a significantly higher prevalence of high-risk MP results and Luminal B BP subtype. High-risk MP/Luminal B BP subtype suggested an association with early recurrence in patients with HR + /HER2- early breast cancer.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Characteristics of a multigene assay (MammaPrint/Blueprint) to predict early recurrence of hormone receptor-positive, HER2-negative breast cancer: a case‒control study (WJOG16722B)

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月26日

查看全文
  • Rurina Watanuki,
  • Hitomi Sakai,
  • Yuri Kimura,
  • Atsushi Yoshida,
  • Yukinori Ozaki,
  • Akemi Kataoka,
  • Natsue Uehiro,
  • Atsushi Fushimi,
  • Hidenori Kamio,
  • Takashi Ikeno,
  • Masashi Wakabayashi,
  • Mayumi Iida,
  • Tsutomu Kawaguchi,
  • Junji Tsurutani,
  • Toshimi Takano

摘要

Background

Hormone receptor-positive, HER2-negative (HR + /HER2-) breast cancer generally has a favorable prognosis; however, early postoperative recurrence markedly reduces survival. Accurate prediction of early recurrence is crucial for personalizing treatment. This case–control study compared MammaPrint (MP) and BluePrint (BP) results between early recurrence patients and matched controls.

Methods

Patients were selected from our previous study, the WJOG15721B cohort (n = 2732). Those with recurrence within three years after surgery were randomly extracted, and controls matched for institution, clinical stage, and number of pathological lymph node metastases were included (n = 124). Tumor samples underwent MP and BP assays to classify recurrence risk and molecular subtypes.

Results

Of 115 submitted tumor samples, 85 were analyzed successfully (43 early recurrence, 42 no recurrence). High-risk MP classification was significantly more frequent in early recurrence patients (79.1% vs. 40.5%, p < 0.001), and Luminal B BP subtype was more common in early recurrence patients (79.1% vs. 38.1%, p < 0.001). High MP risk was associated with high Ki-67 levels and higher nuclear grade. Integrating clinical and genomic risk enhanced prognostic precision: patients with both clinical and genomic high risk had the highest recurrence rate (100%), those with low clinical and genomic risk had the lowest (28.1%), and patients with low clinical but high genomic risk showed an intermediate recurrence rate (57.5%).

Conclusions

Compared with patients without recurrence, those with early recurrence showed a significantly higher prevalence of high-risk MP results and Luminal B BP subtype. High-risk MP/Luminal B BP subtype suggested an association with early recurrence in patients with HR + /HER2- early breast cancer.